PMI Contributions to Fight Malaria


Photograph of an African woman holding hands with her smiling daughter in front of a rugged landscape, while carrying an Insecticide-Treated Net. Photo Credit: Riccardo Gargale, VectorWorks. Courtesty of Photoshare.

Source: Riccardo Gangale, VectorWorks.

When it was launched in 2005, the goal of the President’s Malaria Initiative (PMI) was to reduce malaria-related mortality by 50 percent across 15 high-burden countries in sub-Saharan Africa through a rapid scale-up of four proven and highly effective malaria prevention and treatment measures: insecticide-treated mosquito nets (ITNs); indoor residual spraying (IRS); accurate diagnosis and prompt treatment with artemisinin-based combination therapies (ACTs); and intermittent preventive treatment of pregnant women (IPTp). See PMI Technical Guidance [PDF, 2.4MB] to learn more.

With the passage of the Tom Lantos and Henry J. Hyde Global Leadership against HIV/AIDS, Tuberculosis, and Malaria Act in 2008 [PDF, 239KB], PMI developed a U.S. Government Malaria Strategy for 2009–2014 [PDF, 483KB]. Consistent with this strategy and the increase in annual appropriations supporting PMI, four new countries in sub-Saharan Africa and one regional program in the Greater Mekong Subregion of Southeast Asia were added in 2011.

PMI’s Strategy for 2015–2020 [PDF, 15.9MB] takes into account the progress over the past decade and the new challenges that have arisen. Malaria prevention and control remains a major U.S. foreign assistance objective and PMI's Strategy fully aligns with the U.S. Government's vision of ending preventable child and maternal deaths and ending extreme poverty. It is also in line with the goals articulated in the Roll Back Malaria Partnership's Action and Investment to Defeat Malaria 2016–2030 and World Health Organization's Global Technical Strategy for Malaria 2016–2030. Under the PMI Strategy for 2015–2020, the U.S. Government's goal is to work with PMI-supported countries and partners to further reduce malaria deaths and substantially decrease malaria morbidity, towards the long-term goal of elimination. In FY 2017, thanks to increased funding for PMI from the U.S. Congress, PMI announced plans for a five-country expansion adding programs in Burkina Faso, Cameroon, Côte d’Ivoire, Niger and Sierra Leone, which grew PMI’s reach to 24 malaria-endemic countries in sub-Saharan Africa, including those with the highest burden, and three programs in the Greater Mekong Subregion of Southeast Asia.


PMI is an interagency initiative led by the U.S. Agency for International Development (USAID) and implemented together with the U.S. Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS). It is overseen by a U.S. Global Malaria Coordinator and an Interagency Advisory Group made up of representatives of USAID, CDC/HHS, the Department of State, the Department of Defense, the National Security Council, and the Office of Management and Budget.

PMI partners


U.S. Global Malaria Coordinator, Dr. Kenneth Staley   |   Deputy U.S. Global Malaria Coordinator, Dr. Rick Steketee

Dr. Kenneth Staley

U.S. Global Malaria Coordinator


Dr. Ken Staley was appointed in April 2018 to lead the U.S. President’s Malaria Initiative (PMI), the largest effort in history to control malaria in Africa and the Greater Mekong region in Asia. PMI is a collaborative U.S. Government effort led by the U.S. Agency for International Development (USAID) in conjunction with the Department of Health and Human Services (Centers for Disease Control and Prevention), the Department of State, the White House, and others. As coordinator, Dr. Staley reports to the USAID administrator and has primary responsibility for the oversight and coordination of all resources and international activities of the U.S. Government relating to efforts to combat malaria.

Prior to his appointment, Dr. Staley was a consultant at McKinsey and Company, where he assisted with large public health crisis responses to Ebola and Middle Eastern Respiratory Syndrome and also served clients in the pharmaceutical and medical device industries on strategic and operational topics. Prior to joining McKinsey, Dr. Staley was an executive at Medtronic, where he led several new Medtronic ventures aimed at expanding access to medical technology in emerging economies.

During the George W. Bush administration, Dr. Staley served as the Deputy Assistant Secretary for Counterproliferation (Acting) in the Department of State’s Bureau of International Security and Nonproliferation. His portfolio included preventing trafficking of weapons of mass destruction, their delivery systems, and related materials to and from states and non-state actors of proliferation concern, chemical and biological weapons, multilateral arms control and non-proliferation, and responsible use of chemical and biological sciences.

Prior to his work at the Department of State, he served as Director for Biodefense Policy at the White House Homeland Security Council Biodefense Directorate, where he coordinated implementation of the National Strategy for Pandemic Influenza and development of policies related to biodefense preparedness and response activities for defense against intentional and naturally occurring biological threats.

Dr. Staley received his M.D. from the University of Iowa’s Carver College of Medicine, from which he also received a distinguished alumni award for early career achievement. He also holds a Master of Public Administration from Harvard Kennedy School and an A.B. in Biology from Washington University in Saint Louis.


Dr. Rick Steketee

Deputy U.S. Global Malaria Coordinator


Dr. Rick Steketee was named in July 2018 as the Deputy U.S. Global Malaria Coordinator for PMI. Dr. Steketee is an internationally recognized expert in malaria and a medical epidemiologist with over 30 years of public health experience in infectious diseases. He spent 21 years as an active duty member of the U.S. Public Health Service, with 15 of those years working on malaria at the U.S. Centers for Disease Control and Prevention (CDC).  During that time, he spent approximately 5 years in Malawi, evaluating programmatic approaches to controlling malaria in pregnancy and childhood, eventually becoming CDC’s Malaria Branch Chief in 2000.

Subsequently, Dr. Steketee joined PATH in 2005 and worked as the Science Director for the Malaria Control Program at PATH supporting field work in sub-Saharan African countries.  He was the Director of PATH’s Malaria Control and Elimination Program (MCEP) and Director of the Malaria Control and Elimination Partnership in Africa (MACEPA) since 2015. As the Director of MCEP, he provided leadership across a broad portfolio of malaria programs.

He has worked closely with the World Health Organization (WHO), UNICEF, the World Bank, the Global Fund to Fight HIV, TB and Malaria, and the RBM Partnership to End Malaria and participated on RBM working groups including the Monitoring and Evaluation Working Group, the Harmonization Working Group, the Malaria in Pregnancy Working Group and the Case Management Working Group. Dr. Steketee has participated in numerous WHO Expert Review Groups on malaria and is a current member of the WHO Malaria Policy Advisory Committee.


The PMI funding figures below do not include other U.S. Government funding for malaria activities from the U.S. Agency for International Development (USAID), the U.S. Centers for Disease Control and Prevention (CDC), the National Institutes of Health or the Department of Defense.

Fiscal Year (FY) Budget Focus Countries
2006 $30 million Angola, Tanzania, and Uganda
2007 $154 million + Malawi, Mozambique, Rwanda, and Senegal
2008 $296 million + Benin, Ethiopia (Oromia Region), Ghana, Kenya, Liberia, Madagascar, Mali, and Zambia 
2009 $300 million 15 PMI focus countries
2010 $500 million 15 PMI focus countries
2011 $578 million + DRC, Nigeria, Guinea, Zimbabwe and the Mekong Subregion 
2012 $604 million 19 PMI focus countries and three programs in the Greater Mekong Subregion
2013 $608 million 19 PMI focus countries and three programs in the Greater Mekong Subregion
2014 $619 million 19 PMI focus countries and three programs in the Greater Mekong Subregion
2015 $619 million 19 PMI focus countries and three programs in the Greater Mekong Subregion
2016 $621 million 19 PMI focus countries and three programs in the Greater Mekong Subregion
2017 $723 million 24 PMI focus countries and three programs in the Greater Mekong Subregion
2018 $723 million 24 PMI focus countries and three programs in the Greater Mekong Subregion

Country Selection: The 24 countries in Africa were selected and approved by the U.S. Global Malaria Coordinator and the Interagency Steering Group using the following criteria: high malaria disease burden; national malaria control policies consistent with the internationally accepted standards of the World Health Organization; national capacity to implement such policies; willingness to partner with the U.S. to fight malaria; involvement of other international donors and partners in national malaria control efforts. 


A family in Cambodia smile for the camera in front of a mosquito net. Photo credit: Kharn Lina, URC

Source: Kharn Lina, URC.

Partnerships at national and international levels are key to the success of PMI’s malaria control efforts. PMI’s investments are strategically targeted to support each focus country’s malaria control strategy and plan while coordinating with and leveraging the support of other partners including:

  • Multilateral and bilateral organizations
  • Other U.S. Government agencies and initiatives
  • Private sector partners
  • Foundations
  • Community-based organizations
  • Implementing partners


A group of mosquito sprayers unload a truck and prepare to work. Photo credit: Brant Stewart, RTI.

Source: Brant Stewart, RTI.

The U.S. Government’s leadership and its financial and technical contributions through PMI have been central to the remarkable achievements against malaria. The World Health Organization estimates global efforts have helped reduce malaria deaths by more than 60 percent, saving almost 7 million lives, and preventing more than 1 billion malaria cases between 2000 and 2015.

In PMI focus countries, the gains in malaria control have been impressive since PMI was first launched in June 2005. To date, excluding the five new PMI countries announced in 2017, all 19 PMI focus countries in Africa have data from paired nationwide surveys and have documented declines in all-cause mortality rates among children under five (see Figure below). The large-scale rollout of malaria prevention and treatment measures across sub-Saharan Africa during the past decade has been an important factor in these child survival improvements.

For details on PMI's decade of progress, access the PMI Thirteenth Annual Report – May 2019 [PDF, 10.7MB], or take a quick view of PMI by the Numbers [PDF, 2.6MB].

Reduction in All-Cause Mortality Rates of Children Under Five Years of Age in PMI Focus Countries